Views
Graph
Explorer
Focus
Down
Load 1 level
Load 2 levels
Load 3 levels
Load 4 levels
Load all levels
All
Dagre
Focus
Down
Load 1 level
Load 2 levels
Load 3 levels
Load 4 level
Load all levels
All
Tree
SpaceTree
Focus
Expanding
Load 1 level
Load 2 levels
Load 3 levels
Down
All
Down
Radial
Focus
Expanding
Load 1 level
Load 2 levels
Load 3 levels
Down
All
Down
Box
Focus
Expanding
Down
Up
All
Down
Page ✓
Article
Outline
Document
Down
All
Canvas
Time
Timeline
Calendar
Request email digest
Past 24 hours
Past 2 days
Past 3 days
Past week
Add
Add page
Add comment
Add citation
Edit
Edit page
Delete page
Share
Link
Bookmark
Embed
Social media
Login
Member login
Register now for a free account
🔎
Patient-important outcomes aren't improved
OpposingArgument
1
#113932
There is no evidence that existing commercial serological assays improve patient-important outcomes.
Immediately related elements
How this works
-
Controlling Infectious Diseases »
Controlling Infectious Diseases
Controlling Infectious Diseases☜Mapping the issues around endemic diseases—such as malaria, measles, influenza, HIV, Dengue and West Nile Virus—with the aims of identifying improved control strategies and of providing insights into to the work of mathematical biologists, epidemiologists and public health officials in this field.☜F1CEB7
▲
Diseases »
Diseases
Diseases☜☜FFB597
▲
TB »
TB
TB☜The Wikipedia page on Tuberculosis is embedded in the Details, and will be updated whenever the Wikipedia page updates.☜D3B8AB
▲
Diagnosis of Tuberculosis »
Diagnosis of Tuberculosis
Diagnosis of Tuberculosis☜☜FFB597
▲
Commercial Serological Tests for TB »
Commercial Serological Tests for TB
Commercial Serological Tests for TB☜☜59C6EF
■
Patient-important outcomes aren't improved
Patient-important outcomes aren't improved☜There is no evidence that existing commercial serological assays improve patient-important outcomes.☜EF597B
Heading
Summary
Click the button to enter task scheduling information
Open
Details
Enter task details
Message text
Select assignee(s)
Due date (click calendar)
RadDatePicker
RadDatePicker
Open the calendar popup.
Calendar
Title and navigation
Title and navigation
<<
<
November 2024
>
<<
November 2024
S
M
T
W
T
F
S
44
27
28
29
30
31
1
2
45
3
4
5
6
7
8
9
46
10
11
12
13
14
15
16
47
17
18
19
20
21
22
23
48
24
25
26
27
28
29
30
49
1
2
3
4
5
6
7
Reminder
No reminder
1 day before due
2 days before due
3 days before due
1 week before due
Ready to post
Copy to text
Enter
Cancel
Task assignment(s) have been emailed and cannot now be altered
Lock
Cancel
Save
Comment graphing options
Choose comments:
Comment only
Whole thread
All comments
Choose location:
To a new map
To this map
New map options
Select map ontology
Options
Standard (default) ontology
College debate ontology
Hypothesis ontology
Influence diagram ontology
Story ontology
Graph to private map
Cancel
Proceed
+Komentarai (
0
)
- Komentarai
Komentuoti
Newest first
Oldest first
Show threads
+Citavimą (
1
)
- Citavimą
Pridėti citatą
List by:
Citerank
Map
Link
[1]
Commercial Serodiagnostic Tests for Diagnosis of Tuberculosis
Cituoja:
World Health Organization - WHO Policy Statement – 2011
Cituojamas:
David Price
9:31 PM 22 July 2011 GMT
Citerank:
(7)
113930
Inconsistent findings
Commercial serological tests for TB provide findings
13
EF597B
,
113931
Imprecise findings
Commercial serological tests for TB provide imprecise findings.
13
EF597B
,
113933
Adverse impact on patient-safety
High proportions of false-positive and false-negative results adversely impact patient safety.
13
EF597B
,
129647
Inconsistent findings
Commercial serological tests for TB provide findings
13
EF597B
,
129648
Imprecise findings
Commercial serological tests for TB provide imprecise findings.
13
EF597B
,
129649
Patient-important outcomes aren't improved
There is no evidence that existing commercial serological assays improve patient-important outcomes.
13
EF597B
,
129650
Adverse impact on patient-safety
High proportions of false-positive and false-negative results adversely impact patient safety.
13
EF597B
URL:
http://whqlibdoc.who.int/publications/2011/9789241502054_eng.pdf
Ištrauka -
Conclusions: Commercial serological tests provide inconsistent and imprecise findings resulting in highly variable values for sensitivity and specificity. There is no evidence that existing commercial serological assays improve patient-important outcomes, and high proportions of false positive and false-negative results adversely impact patient safety. Overall data quality was graded as very low and it is strongly recommended that these tests not be used for the diagnosis of pulmonary and extra-pulmonary TB.
+About
- About
Redagavo:
David Price
NodeID:
#113932
Node type:
OpposingArgument
Įvedimo data (GMT):
7/22/2011 9:29:00 PM
Paskutinės redakcijos data (GMT laikas):
7/22/2011 9:29:00 PM
Show other editors
Įeinančios sąsajos:
0
Išeinančios sąsajos:
0
Vidutinis vertinimas:
0
by
0
vartotojai
x
Select file to upload